Evaluation of NT-proBNP in Chronic Inflammatory Bowel Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

159 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-28

Study Completion Date

2017-08-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

NT-proBNP is a major diagnostic and prognostic marker in cardiology, but it is also a new marker for biological inflammation, especially in rheumatology.

Its evaluation in chronic inflammatory bowel disease was carried out in a preliminary study, the OPERA study where in a population of 12 patients showed an increase in NT-proBNP correlated with the biological and endoscopic activity of the disease. This larger study is therefore a pilot study that could see NTproBNP as a new biomarker of inflammation in MICI.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessing Cardiovascular Dysfunction Pre- & Post-treatment in Inflammatory Bowel Diseases

NCT03615287

Inflammatory Bowel Diseases

UNKNOWN

Novel Biomarkers in Inflammatory Bowel Disease

NCT03833310

Inflammatory Bowel Diseases

COMPLETED

Population Based Evaluation of the Use of TNFα Antagonists in Pregnant Women With Inflammatory Bowel Diseases

NCT03134508

Inflammatory Bowel Diseases

COMPLETED

Study to Evaluate the Epidemiology and the Characteristics "Omics" in Patients Recently Diagnosed of Inflammatory Bowel Disease in Spain

NCT03689257

Inflammatory Bowel Diseases

COMPLETED

Autonomic and Cytokines Profiles of Patients With Ulcerative Proctitis

NCT03259659

Inflammatory Bowel Diseases

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Bowel Diseases NT-pro-BNP

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with CD or RCH

Group Type OTHER

Evaluate the blood level of NTproBNP

Intervention Type OTHER

Evaluate the blood level of NTproBNP in patients with MICI compared to a healthy control population.

The control population

Group Type OTHER

Evaluate the blood level of NTproBNP

Intervention Type OTHER

Evaluate the blood level of NTproBNP in patients with MICI compared to a healthy control population.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Evaluate the blood level of NTproBNP

Evaluate the blood level of NTproBNP in patients with MICI compared to a healthy control population.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult subjects (age 18 years)
* MICI Group: Patients monitored for probable HC or MC
* Control group: Patients referred for consultation in gastroenterology with a clinical and endoscopic picture eading to the diagnosis of TF I
* Person who agreed to participate in the study
* Patient covered by social insurance

Exclusion Criteria

* Causes of increased concentrations of natriuretic peptides: acute heart failure, acute or chronic pulmonary disease with right ventricular repercussion, valvulopathies, primary or secondary HVG, atrial fibrillation cardiac arrhythmia, chronic systolic dysfunction, hyperthyroidism, Addison's disease, hyperaldosteronism Primary, diabetes, cirrhosis with ascites, cancers, chronic renal insufficiency.
* Inflammatory and autoimmune diseases (excluding MC and RCH), chronic inflammatory syndrome
* Ongoing treatment that may affect the concentration of natriuretic peptides: ACE inhibitor, angiotensin II receptor antagonists, diuretics
* Patient deprived of liberty or protected major (under guardianship or curatorship)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No